Related Experiment Video
Updated: Oct 17, 2026

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
Current and novel agents for the treatment of cytomegalovirus retinitis
1Department of Clinical Ophthalmology, Institute of Ophthalmology, London, England.
Abstract:
The incidence of cytomegalovirus (CMV) retinitis appears to be declining with improved treatment protocols for HIV and prophylaxis protocols for other high risk patients. Despite this, CMV retinitis remains a major cause of visual loss in patients who are severely immunocompromised. Treatment options are evolving in the light of viral resistance, new methods of drug delivery, new drugs, and the increased potential for improvement of immune function that modern antiretroviral therapy provides. In this article, we review the changing options available for the management of CMV retinitis and discuss possible therapeutic agents for the future.
Related Concept Videos
Cytomegalovirus Disease
Antiviral Nucleoside Inhibitors
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Inhibitors of Viral Protein Synthesis
Diabetic Retinopathy
Inhibitors Of Virion Release
